摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4’-溴-2’-甲基苯乙酮 | 65095-33-2

中文名称
4’-溴-2’-甲基苯乙酮
中文别名
4'-溴-2'-甲基苯乙酮;2-甲基-4-溴苯乙酮
英文名称
1-(4-bromo-2-methylphenyl)ethanone
英文别名
1-(4-bromo-2-methylphenyl)ethan-1-one
4’-溴-2’-甲基苯乙酮化学式
CAS
65095-33-2
化学式
C9H9BrO
mdl
——
分子量
213.074
InChiKey
UJPLWOQOYGUXEF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    278 °C
  • 密度:
    1.388
  • 闪点:
    85 °C

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2914700090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温且干燥环境下使用。

SDS

SDS:3c407037473f5339d6a90fec09367e99
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4’-Bromo-2’-methylacetophenone
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4’-Bromo-2’-methylacetophenone
CAS number: 65095-33-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9BrO
Molecular weight: 213.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4’-溴-2’-甲基苯乙酮甲醇 、 sodium tetrahydroborate 作用下, 以81 %的产率得到1-(4-bromo-2-methylphenyl)ethanol
    参考文献:
    名称:
    [EN] GPR84 ANTAGONISTS AND USES THEREOF
    [FR] ANTAGONISTES DU GPR84 ET LEURS UTILISATIONS
    摘要:
    本发明提供了I式化合物,其组成物和使用相应物质抑制GPR84以及治疗GPR84介导的疾病的方法。
    公开号:
    WO2022167445A1
  • 作为产物:
    参考文献:
    名称:
    [EN] HEPATITIS C VIRUS INHIBITORS
    [FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
    摘要:
    本公开涉及化合物、组合物和用于治疗丙型肝炎病毒(HCV)感染的方法,其化学式如下(I)。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
    公开号:
    WO2012154777A1
点击查看最新优质反应信息

文献信息

  • MTA-Cooperative PRMT5 Inhibitors
    申请人:Mirati Therapeutics, Inc.
    公开号:US20210078994A1
    公开(公告)日:2021-03-18
    The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    本发明涉及抑制蛋白精氨酸N-甲基转移酶5(PRMT5)活性的化合物。具体而言,本发明涉及化合物、药物组合物和使用方法,例如使用本发明的化合物和药物组合物治疗癌症的方法。
  • CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
    申请人:Renz Martin
    公开号:US20100331320A1
    公开(公告)日:2010-12-30
    This invention relates to novel compounds of the Formula Ik, Im 1 , Im 2 , Im 5 , In 1 , In 2 , In 5 , Io 1 , Io 2 , Io 5 , Ip 1 , Ip 3 , pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
    这项发明涉及到Ik、Im1、Im2、Im5、In1、In2、In5、Io1、Io2、Io5、Ip1、Ip3的新化合物,以及其药学上可接受的盐和药物组合物,这些化合物对于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病是有用的。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法。
  • [EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2015005901A1
    公开(公告)日:2015-01-15
    The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    本公开涉及抗病毒化合物,更具体地涉及能够抑制由丙型肝炎病毒(HCV)编码的NS5A蛋白功能的化合物组合,包括这种组合的组合物,以及抑制NS5A蛋白功能的方法。
  • [EN] COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS UTILISÉS COMME INHIBITEURS DE KINASE
    申请人:REDX PHARMA PLC
    公开号:WO2017103611A1
    公开(公告)日:2017-06-22
    This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    这项发明涉及新颖的化合物。该发明的化合物是酪氨酸激酶抑制剂。具体来说,该发明的化合物可用作布鲁顿氏酪氨酸激酶(BTK)的抑制剂。该发明还考虑了利用这些化合物治疗通过抑制布鲁顿氏酪氨酸激酶可治疗的疾病,例如癌症、淋巴瘤、白血病和免疫性疾病。
  • [EN] CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE<br/>[FR] BI-HÉTÉROCYCLES CONDENSÉS UTILISÉS EN TANT QU'AGENTS INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
    申请人:BIOGEN MA INC
    公开号:WO2021087112A1
    公开(公告)日:2021-05-06
    Provided are compounds of Formula (I): Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A1, B1, B2, Q1 and Q2 are as defined herein; and methods for their use and production.
    提供的是化合物的化学式(I):化学式(I)或其药用可接受的盐,其中R1、R2、R3、R4、R5、R6、A1、B1、B2、Q1和Q2如本文所定义;以及它们的使用和生产方法。
查看更多